MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.

NCT01498952 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Unresectable or Metastatic Hepatocellular Carcinoma (HCC)

Interventions

DRUG: MEDI-573 (1 of 3 doses)
DRUG: Sorafenib

Sponsor

MedImmune LLC